Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suplineuro LC is a fixed-dose combination nutraceutical developed by Neurogenics Therapeutics, primarily indicated for the management of peripheral and diabetic neuropathy. The product contains levocarnitine, methylcobalamin, and folic acid. Levocarnitine facilitates the transport of long-chain fatty acids into mitochondria, supporting energy production essential for nerve cell repair and function. Methylcobalamin, an active form of Vitamin B12, promotes the synthesis of the myelin sheath and aids in nerve regeneration. Folic acid is a critical cofactor for DNA synthesis and the regulation of homocysteine levels, which, when elevated, can contribute to nerve damage. Together, these components work synergistically to alleviate neuropathic symptoms and improve overall nerve health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suplineuro LC.